Scarica l'app Stockscreener
0.9987
6.66%
-0.0713
Pre-mercato:
.98
-0.0187
-1.87%
Precedente Chiudi:
$1.07
Aprire:
$1.07
Volume 24 ore:
189.91K
Relative Volume:
0.05
Capitalizzazione di mercato:
$23.40M
Reddito:
-
Utile/perdita netta:
$-178.01M
Rapporto P/E:
-0.1199
EPS:
-8.326
Flusso di cassa netto:
$-7.87M
1 W Prestazione:
-27.63%
1M Prestazione:
-5.78%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.9949
$1.07
Intervallo di 1 settimana:
$0.9949
$1.37
Portata 52W:
$0.81
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
Nome
Lunai Bioworks Inc
Settore
Industria
Telefono
45 39179840
Indirizzo
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Confronta LNAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
0.9987 | 25.07M | 0 | -178.01M | -7.87M | -8.326 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lunai Bioworks Inc Borsa (LNAI) Ultime notizie
Lunai bioworks identifies three parkinsons disease subtypes By Investing.com - Investing.com South Africa
Lunai bioworks identifies three parkinsons disease subtypes - Investing.com
Lunai Bioworks identifies three Parkinson's disease subtypes - marketscreener.com
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market - Barchart.com
Ready to Jump After Recent Trade: Lunai Bioworks Inc (LNAI) - setenews.com
Lunai Bioworks (LNAI) Stock Analysis Report | Financials & Insights - Benzinga
Lunai Bioworks enters sales agreement with Dawson James SecuritiesSEC filing - marketscreener.com
Lunai Bioworks Enters Sales Agreement with Dawson James - TipRanks
Does Lunai Bioworks Inc (LNAI) offer a good opportunity for investors? - Setenews
Lunai Bioworks’ immune cell therapy shows tumor regression, wins first license - MSN
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy - MSN
Lunai Bioworks - The Pharma Letter
Lunai Bioworks lands first licensing deal for off-the-shelf cancer immunotherapy - The Pharma Letter
There is no way Lunai Bioworks Inc (LNAI) can keep these numbers up - Setenews
Lunai Bioworks Secures $3.1M in Private Placement - The Globe and Mail
Lunai Bioworks Inc (2Q50.MU) latest stock news and headlines - Yahoo Finance Australia
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Shares Decline Amidst New Licensing Agreement - Stocks Telegraph
Lunai Bioworks sells 3,133,333 shares in private financing deal - Stock Titan
LNAI Stock: Surging or Slipping? - StocksToTrade
Lunai Bioworks (LNAI) Stock: Plummets 14.2% Despite Breakthrough in Cancer Immunotherapy - parameter.io
Lunai Bioworks Shares Rise After Company Secures Licensing Intent for Dendritic Cell Therapy - marketscreener.com
Lunai Bioworks: Stock Surge or Bubble? - timothysykes.com
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy By Investing.com - Investing.com South Africa
LNAI's Groundbreaking Immune Cell Therapy Advances with Key Lice - GuruFocus
Lunai Bioworks Secures First Licensing LOI Following Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - MarketScreener
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - Sahm
Lunai Bioworks rises on early licensing interest in DCCT therapy | Tap to know more | Inshorts - Inshorts
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Routine Trading Amid Price Decline - Stocks Telegraph
Lunai Bioworks Inc (2Q50.MU) options chain - Yahoo Finance Australia
Lunai Bioworks Inc. (LNAI) -13.9% in Normal Trading: Price Declines Amid Routine Trading - Stocks Telegraph
What is the current Price Target and Forecast for Lunai Bioworks Inc. (LNAI) - Zacks Investment Research
Lunai Bioworks Inc. announced that it expects to receive $3.133333 million in funding - marketscreener.com
Lunai Bioworks Inc Com (LNAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Lunai Bioworks Inc (2Q50.MU) analyst ratings, estimates and forecasts - Yahoo Finance Australia
Lunai Bioworks Inc (2Q50.MU) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Are Smart Investors Making the Right Decision? Lunai Bioworks Inc (LNAI) - Setenews
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - Greenville Online
Lunai Bioworks Inc. (LNAI) stock price, news, quote and history - Yahoo Finance Australia
Lunai Bioworks: Fiscal Q1 Earnings Snapshot - New Haven Register
Lunai Bioworks Inc. Reports Earnings Results for the First Quarter Ended September 30, 2025 - MarketScreener
[10-Q] Lunai Bioworks Inc. Quarterly Earnings Report | RENB SEC FilingForm 10-Q - Stock Titan
A better buy-in window may exist right now for Lunai Bioworks Inc (LNAI) - Setenews
A Mandatory Rebranding: Lunai Bioworks Emerges from Enochian’s Ashes - Ad-hoc-news.de
Lunai Bioworks Inc. (2Q50.F) Company Profile & Facts - Yahoo! Finance Canada
Lunai Bioworks Inc. (LNAI) Stock Major Holders - Yahoo! Finance Canada
Top Biotech Stocks To Follow NowNovember 5th - MarketBeat
Lunai Bioworks Inc. (LNAI) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
Lunai Bioworks Inc. (LNAI) latest press releases and corporate news - Yahoo Finance UK
Top Biotech Stocks To Follow Now – November 5th - Defense World
Lunai Bioworks Inc (2Q50.MU) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Lunai Bioworks Inc Azioni (LNAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):